All In Biotech

BLA 761053 · Genentech INC

Ocrevus

Ocrelizumab · Injection · CD20-directed Cytolytic Antibody

NovelBreakthrough therapyPriority review

Last checked: Nov 20, 2026Latest source record: May 8, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Mar 28, 2017

Approved uses

3

Original approval plus efficacy supplements

Registered trials

89

45 Phase 3, 24 recruiting

FAERS reports

62,729

31,724 serious, 1,540 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 14, 2026.

OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more. OCREVUS is a CD20-directed cytolytic antibody indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 ) Primary progressive MS, in adults ( 1 ) Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more ( 1 )

Mechanism: The precise mechanism by which ocrelizumab exerts its therapeutic effects in multiple sclerosis is unknown, but is presumed to involve binding to CD20, a cell surface antigen present on pre-B and mature B lymphocytes. Following cell surface binding to B lymphocytes, ocrelizumab results in antibody-dependent cellular cytolysis and complement-mediated lysis.

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • OCREVUS · OCRELIZUMAB 30MG/1ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ocrelizumab" as an intervention, any sponsor and status, largest first.

All 89 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • covid-1911,587
  • fatigue6,297
  • urinary tract infection3,818
  • headache3,311
  • multiple sclerosis3,123
  • multiple sclerosis relapse2,818
  • gait disturbance2,756
  • asthenia2,735
  • nasopharyngitis2,601
  • pain2,585
  • fall2,559
  • drug ineffective2,491

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20081
20091
201010
201113
201217
20137
201412
201510
201630
20171,129
20184,995
20196,275
20205,549
20217,193
202211,405
20238,927
20249,566
20254,551
20263,037

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ocrevus (Ocrelizumab)

2024 spending

$195M

Beneficiaries

3,085

5,163 claims

Per beneficiary

$63,231

$1,932.14 per unit

View as table
YearSpending
2020$81,042,687
2021$96,636,442
2022$123,045,548
2023$157,049,386
2024$195,066,362

Part B: Ocrevus (Ocrelizumab) · HCPCS J2350

2024 spending

$669M

Beneficiaries

11,764

20,976 claims

Per beneficiary

$56,845

2024 ASP limit $59.64 per unit

View as table
YearSpending
2020$618,776,537
2021$608,203,407
2022$693,652,844
2023$697,178,191
2024$668,719,044

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 143 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.